• International Society of Paediatric Oncology Europe Neuroblastoma

Risk groups

Many factors determine the chances of successfully treating patients with neuroblastoma.

Patients are organised into different risk groups to decide on the best treatment, based on a number of factors including:

  • patient age
  • extent of the tumour (whether it is localised to one place or has spread to other parts of the body)
  • histopathology of the tumour - how the cells appear under the microscope
  • biology of the tumour itself – how the chromosomes or individual genes (such as MYCN) are altered

Based on these factors, patients are divided into low, intermediate and high risk groups. This gives information about the chances of a cure and helps to determine the treatment plan. In general, patients in the high risk group need more treatment than those in the intermediate group, who in turn need more treatment than those in the low risk group.

The extent of the tumour is described by a staging system. Stage 1 (L1 in the new staging system) describes localised disease, while stage 4 (M in the new system) is metastatic disease meaning that the neuroblastoma has spread from the primary tumour to other sites in the body.

(Images from Pediatric Surgery at UCSF)

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information


SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.